Q
Q32 Bio Inc (QTTB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$8.29
-0.42 (-4.82%)
Market Cap: $260.64M
Last updated: Nov 17, 2026 at 11:06 AM ET
Q32 Bio Inc (QTTB) P/E Ratio & Valuation History
Q32 Bio (QTTB) trades at 2.5x trailing earnings and 5.2x sales. Its price to book ratio is 1.0x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | 2.5x |
| Forward P/E | N/A |
| Price to sales | 5.2x |
| Price to book | 1.0x |
| PEG | N/A |
Valuation History
Over the 5 of the 8 year ends shown that have a P/S, its P/S ranged from 0.8x in 2025 to 528.7x in 2019. 2025 was the lowest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $3.32 | 1.4x | 0.8x | 1.0x |
| 2024 | $3.44 | N/A | N/A | 7.4x |
| 2023 | $10.94 | N/A | N/A | N/A |
| 2022 | $22.66 | N/A | 22.5x | 0.4x |
| 2021 | $65.47 | N/A | 5.5x | 1.0x |
| 2020 | $203.06 | N/A | 193.0x | 3.0x |
| 2019 | $372.30 | N/A | 528.7x | 3.5x |
| 2018 | $402.16 | N/A | N/A | 3.9x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About QTTB
Is QTTB stock overvalued?
GNG's valuation label for QTTB is Overvalued.
What is QTTB's price to sales ratio?
Q32 Bio has a price to sales ratio of 5.2x.
QTTB pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors